Abstract
Human adenovirus (AdV) infection and EBV-lymphoproliferative disease (LPD) are serious complications following allogeneic stem cell transplantation. In the healthy individual these viruses cause minor, self-limiting diseases but in the immunocompromised patient they are responsible for significant morbidity and mortality. The limitations of anti-viral drugs and a better understanding of the cellular immune response to viral pathogens have prompted interest in developing adoptive immunotherapy for transplant patients. Ex vivo expanded cytotoxic T lymphocytes (CTLs) specific for EBV have been used effectively both as prophylaxis against EBV-LPD and as treatment of established EBV+ lymphoma. To generate CTLs specific for AdV, we infected immature dendritic cells with virus, in the presence of lipid, and subsequently used these cells to stimulate PBMNCs. Cytotoxicity assays showed that the resulting CTLs specifically lysed AdV-expressing targets and that this was mediated predominantly by CD4+ T cells. To generate CTLs specific for both AdV and EBV, we developed a CD40 ligand co-culture system to infect B-lymphoblastoid cell lines (LCLs) with high efficiency. PBMNCs from healthy AdV-seropositive donors were stimulated weekly with autologous AdV+-LCLs. Chromium release assays demonstrated that the resultant CTLs had specificity against both EBV and AdV and that this was mediated by both CD4+ and CD8+ T cells. Our findings have potential implications for post-transplant AdV and EBV immunotherapy in recipients of allogeneic stem cell transplants. Bone Marrow Transplantation (2001) 27, 53–64.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tosato G . The Epstein–Barr virus and the immune system Adv Cancer Res 1987 49: 75–125
Hale GA, Heslop HE, Krance RA et al. Adenovirus infection after pediatric bone marrow transplantation Bone Marrow Transplant 1999 23: 277–282
Shapiro RS, McClain K, Frizzera G et al. Epstein–Barr virus-associated B-cell lymphoproliferative disorders following bone marrow transplantation Blood 1988 71: 1234–1243
Zutter MM, Martin PJ, Sale GE et al. Epstein–Barr virus lymphoproliferation after bone marrow transplantation Blood 1988 72: 520–529
Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation New Engl J Med 1994 330: 1185–1191
Lucas KG, Burton RL, Zimmerman SE et al. Semiquantitative Epstein–Barr virus-(EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation Blood 1998 91: 3654–3661
Lucas KG, Small TN, Heller G et al. The development of cellular immunity to Epstein–Barr virus after allogeneic bone marrow transplantion Blood 1996 87: 2594–2603
Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T-lymphocytes Nature Med 1996 2: 551–555
Rooney CM, Smith CA, Loftin SK et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus related lymphoproliferation Lancet 1995 345: 9–13
Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients Blood 1998 92: 1549–1555
Culmann B, Gomard E, Kleny MP et al. Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein J Immunol 1991 146: 1560–1565
Chu ET, Lareau M, Rosenwasser LJ et al. Antigen presentation by EBV-B cells to resting and activated T cells: role of interleukin 1 J Immunol 1985 134: 1676–1681
Smith CA, Woodruff LS, Kitchingman GR, Rooney CM . Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cells in vitro J Virol 1996 70: 6733–6740
Smith CA, Woodruff LS, Rooney CM, Kitchingman GR . Extensive cross-reactivity of adenovirus-specific cytotoxic T-cells Hum Gene Ther 1998 9: 1419–1427
Flomenberg P, Babbitt J, Drobyski WR et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients J Infect Dis 1994 169: 775–781
Cohen JI . The biology of Epstein–Barr virus: lessons learned from the virus and the host Curr Opin Immunol 1999 11: 365–370
Horwitz MS, Sarvetnick N . Viruses, host-responses, and autoimmunity Immunol Rev 1999 169: 241–253
Flomenberg P, Piaskowski V, Truitt RL, Casper JT . Characterization of human proliferative T cell responses to adenovirus J Infect Dis 1995 171: 1090–1096
Hromas R, Cornetta K, Srour E et al. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation Blood 1994 84: 1689–1690
Brodsky FM, Lem L, Solache A, Bennett EM . Human pathogen subversion of antigen presentation Immunol Rev 1999 168: 199–215
Hengel H, Koszinowski UH . Interference with antigen processing by viruses Curr Opin Immunol 1997 9: 470–476
Wold WS, Doronin K, Toth K et al. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic Curr Opin Immunol 1999 11: 380–386
Zhong L, Granelli-Piperno A, Choi Y, Steinman RM . Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells Eur J Immunol 1999 29: 964–972
Zhou LJ, Tedder TF . CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells Proc Natl Acad Sci USA 1996 93: 2588–2592
Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood J Exp Med 1994 180: 83–93
Banchereau J, Steinman RM . Dendritic cells and the control of immunity Nature 1998 392: 245–252
Steinman RM . The dendritic cell system and its role in imunogenicity Annu Rev Immunol 1991 9: 271–296
Brossart P, Goldrath AW, Butz EA et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL J Immunol 1997 158: 3270–3276
De Bruijn ML, Schuurhuis DH, Vierboom MP et al. Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I restricted protection to HPV-16 induced tumor cells Cancer Res 1998 58: 724–731
Nair SK, Hull S, Coleman D et al. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA Int J Cancer 1999 82: 121–124
Ribas A, Butterfield LH, McBride WH et al. Genetic immunization for the melanoma antigen MART-1/melan-A using recombinant adenovirus transduced murine dendritic cells Cancer Res 1997 57: 2865–2869
Porgador A, Gilboa E . Bone-marrow generated dendritic cells pulsed with a class-I restricted peptide are potent inducers of cytotoxic T lymphocytes J Exp Med 1995 182: 255–260
Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 Science 1997 275: 1320–1323
Huang S, Endo RI, Nemerow GR . Upregulation of integrins αvβ3 and αvβ5 on human monocytes and T-lymphocytes facilitates adenovirus-mediated gene delivery J Virol 1995 69: 2257–2263
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR . Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment Cell 1993 73: 309–319
Mathias P, Wickham T, Moore M, Nemerow G . Multiple adenovirus serotypes use αv integrins for infection J Virol 1994 68: 6811–6814
van Bergen J, Ossendorp F, Jordens R et al. Get into the groove! Targeting antigens to MHC class II Immunol Rev 1999 172: 87–96
Steinman RM, Inaba K, Turley S et al. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies Hum Immunol 1999 60: 562–567
Acknowledgements
This work was supported by the Hermann von Helmholtz Gemeinschaft (HGF), Deutsche Forschungszentren.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Regn, S., Raffegerst, S., Chen, X. et al. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant 27, 53–64 (2001). https://doi.org/10.1038/sj.bmt.1702752
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702752
Keywords
This article is cited by
-
Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation
Journal of Hematology & Oncology (2013)
-
Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation
Bone Marrow Transplantation (2007)
-
Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity
Bone Marrow Transplantation (2005)
-
Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery
Bone Marrow Transplantation (2005)
-
Cellular immunotherapy for viral infection after HSC transplantation
Nature Reviews Immunology (2005)